Survival Time of Visual Gains after Diabetic Vitrectomy and Its Relationship with Ischemic Heart Disease.
LogMar
ischemic heart disease
post vitrectomy
prognostic factors
type 2 diabetes mellitus
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
02 01 2020
02 01 2020
Historique:
received:
03
11
2019
revised:
13
12
2019
accepted:
24
12
2019
entrez:
8
1
2020
pubmed:
8
1
2020
medline:
15
8
2020
Statut:
epublish
Résumé
Vitrectomy surgery in proliferative diabetic retinopathy improves the vision-related quality of life. However, there is lack of data on the duration of maintenance of visual gains post vitrectomy. This study thus aimed to determine the survival time of visual gains and the prognostic factors of vision loss after vitrectomy surgery for complications of proliferative diabetic retinopathy. A retrospective cohort study was conducted in an ophthalmology clinic in Malaysia. We included 134 patients with type 2 diabetes mellitus on follow-up after vitrectomy for proliferative diabetic retinopathy. Visual acuity was measured using the log of minimum angle of resolution (LogMar). A gain of ≥0.3 LogMar sustained on two subsequent visits was considered evidence of visual improvement post vitrectomy. Subjects were considered to have vision loss when their post-operative visual acuity subsequently dropped by ≥0.3 LogMar. Kaplan-Meier analysis was used to determine the survival time of visual gains. Cox Proportional Hazard regression was used to determine the prognostic factors of vision loss. The median age of patients was 56.00 years (IQR ± 10.00). The median duration of diabetes mellitus was 14.00 years (IQR ± 10.00). Approximately 50% of patients with initial improvement post vitrectomy subsequently experienced vision loss. The survival time, i.e., the median time from surgery until the number of patients with vision loss formed half of the original cohort, was 14.63 months (95% CI: 9.95, 19.32). Ischemic heart disease was a significant prognostic factor of vision loss. Patients with underlying ischemic heart disease (adjusted HR: 1.97, 95% CI: 1.18, 3.33) had a higher risk of vision loss post vitrectomy, after adjusting for other factors. Approximately half the patients with initial visual gains post vitrectomy maintained their vision for at least one year. Ischemic heart disease was a poor prognostic factor for preservation of visual gains post vitrectomy.
Identifiants
pubmed: 31906417
pii: ijerph17010310
doi: 10.3390/ijerph17010310
pmc: PMC6981366
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Chonnam Med J. 2013 Apr;49(1):1-6
pubmed: 23678470
Eye (Lond). 2012 Apr;26(4):576-82
pubmed: 22241020
N Z Med J. 2017 Feb 17;130(1450):69-77
pubmed: 28207726
Prog Retin Eye Res. 2008 Mar;27(2):161-76
pubmed: 18249026
JAMA. 2001 Jul 4;286(1):64-70
pubmed: 11434828
Curr Diabetes Rev. 2017;13(1):81-86
pubmed: 26456361
PLoS One. 2019 Aug 20;14(8):e0220726
pubmed: 31430299
Am J Ophthalmol. 2013 Apr;155(4):757-63, 763.e1-2
pubmed: 23317651
Diabetes Metab Syndr. 2015 Apr-Jun;9(2):98-103
pubmed: 25470640
JAMA Ophthalmol. 2016 Oct 1;134(10):1111-1118
pubmed: 27490785
J Thromb Thrombolysis. 2004 Oct;18(2):89-101
pubmed: 15789175
JAMA Ophthalmol. 2017 Sep 1;135(9):926-932
pubmed: 28750122
Circ Res. 2003 Feb 7;92(2):151-8
pubmed: 12574142
Am J Cardiol. 2001 Feb 15;87(4):456-9, A6
pubmed: 11179535
Diabetologia. 2010 Oct;53(10):2147-54
pubmed: 20596693
Ophthalmology. 1989 Oct;96(10):1495-500
pubmed: 2587044
Korean J Ophthalmol. 2017 Jun;31(3):217-229
pubmed: 28534343
Ophthalmology. 1991 Jan;98(1):18-22
pubmed: 2023726
Nippon Ganka Gakkai Zasshi. 2008 Feb;112(2):141-7
pubmed: 18318275
Br J Ophthalmol. 2008 Mar;92(3):365-8
pubmed: 18303158
Clin Exp Ophthalmol. 2019 Jul;47(5):598-604
pubmed: 30663192
Diabet Med. 2013 Apr;30(4):387-98
pubmed: 23331210
Circulation. 2003 Mar 25;107(11):1479-85
pubmed: 12654603
JAMA Ophthalmol. 2019 Oct 3;:
pubmed: 31580383
Ophthalmic Epidemiol. 2016;23(2):94-8
pubmed: 26954846
Br J Ophthalmol. 1996 Jul;80(7):640-3
pubmed: 8795378
Ophthalmologica. 1993;206(2):83-8
pubmed: 8272329
Am J Ophthalmol. 2008 Jun;145(6):1031-1036
pubmed: 18400203
Diabetes Care. 2012 Mar;35(3):556-64
pubmed: 22301125
Med J Malaysia. 2010 Sep;65(3):180-6
pubmed: 21939164
J Clin Hypertens (Greenwich). 2010 Oct;12(10):820-5
pubmed: 21029347
Arch Ophthalmol. 1987 Apr;105(4):503-7
pubmed: 2436604
Clin Exp Ophthalmol. 2005 Aug;33(4):373-8
pubmed: 16033349
Cardiovasc Res. 2013 Jan 1;97(1):143-52
pubmed: 23002242
Diabetes Obes Metab. 2019 Mar;21(3):467-478
pubmed: 30280465
Medicine (Baltimore). 2017 Mar;96(10):e6263
pubmed: 28272234
JAMA Ophthalmol. 2017 Jun 1;135(6):586-593
pubmed: 28472362